JP7837345B2 - Tリンパ球結合アプタマー - Google Patents

Tリンパ球結合アプタマー

Info

Publication number
JP7837345B2
JP7837345B2 JP2023557840A JP2023557840A JP7837345B2 JP 7837345 B2 JP7837345 B2 JP 7837345B2 JP 2023557840 A JP2023557840 A JP 2023557840A JP 2023557840 A JP2023557840 A JP 2023557840A JP 7837345 B2 JP7837345 B2 JP 7837345B2
Authority
JP
Japan
Prior art keywords
aptamer
cancer
cells
cell
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023557840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553193A5 (cg-RX-API-DMAC7.html
JP2023553193A (ja
Inventor
ガイ ニーヴ,
イリット カルミ-レヴィ,
エレズ ラヴィ,
ネタ ジロニー-ハニン,
ゾハール ポード,
ネリア レイス,
オハッド グレイチ,
ロニット ファーリ,
Original Assignee
アーミューン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーミューン リミテッド filed Critical アーミューン リミテッド
Publication of JP2023553193A publication Critical patent/JP2023553193A/ja
Publication of JP2023553193A5 publication Critical patent/JP2023553193A5/ja
Application granted granted Critical
Publication of JP7837345B2 publication Critical patent/JP7837345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023557840A 2020-12-03 2021-12-03 Tリンパ球結合アプタマー Active JP7837345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063121080P 2020-12-03 2020-12-03
US63/121,080 2020-12-03
US202163257402P 2021-10-19 2021-10-19
US63/257,402 2021-10-19
PCT/IB2021/000849 WO2022118077A2 (en) 2020-12-03 2021-12-03 T-lymphocyte binding aptamers

Publications (3)

Publication Number Publication Date
JP2023553193A JP2023553193A (ja) 2023-12-20
JP2023553193A5 JP2023553193A5 (cg-RX-API-DMAC7.html) 2024-12-11
JP7837345B2 true JP7837345B2 (ja) 2026-03-30

Family

ID=80446452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557840A Active JP7837345B2 (ja) 2020-12-03 2021-12-03 Tリンパ球結合アプタマー

Country Status (5)

Country Link
US (1) US12146140B2 (cg-RX-API-DMAC7.html)
EP (1) EP4256057A2 (cg-RX-API-DMAC7.html)
JP (1) JP7837345B2 (cg-RX-API-DMAC7.html)
IL (1) IL303374A (cg-RX-API-DMAC7.html)
WO (1) WO2022118077A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146140B2 (en) 2020-12-03 2024-11-19 Aummune Ltd. T-lymphocyte binding aptamers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143150A1 (en) 2016-02-19 2017-08-24 City Of Hope Bi-specific aptamer
CN107129988A (zh) 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690441A1 (en) * 2012-07-26 2014-01-29 Rheinische Friedrich-Wilhelms-Universität Bonn Method of determining a protein in a sample
WO2018017827A1 (en) 2016-07-22 2018-01-25 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific notch inhibition and related methods and compositions
WO2019035763A1 (en) 2017-08-16 2019-02-21 Agency For Science, Technology And Research APTAMERS FOR DETECTION OF ZIKA FLAVIVIRAL PROTEIN
US10584340B2 (en) * 2017-09-29 2020-03-10 University Of Florida Research Foundation, Inc. Tau protein-binding DNA aptamers with capture/detection and therapeutic utilities in tauopathy-related neurodegenerative disorders
CN113423833B (zh) 2018-09-28 2024-09-17 奥曼尼提纳米有限公司 用于选择功能性适体的方法和组合物
US20230193286A1 (en) 2020-05-20 2023-06-22 Aummune Ltd. Cytotoxic t-lymphocyte binding aptamers
US20230193285A1 (en) 2020-05-20 2023-06-22 Aummune Ltd. Bispecific personalized aptamers
US12146140B2 (en) 2020-12-03 2024-11-19 Aummune Ltd. T-lymphocyte binding aptamers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143150A1 (en) 2016-02-19 2017-08-24 City Of Hope Bi-specific aptamer
CN107129988A (zh) 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用

Also Published As

Publication number Publication date
WO2022118077A2 (en) 2022-06-09
EP4256057A2 (en) 2023-10-11
US20220186223A1 (en) 2022-06-16
US12146140B2 (en) 2024-11-19
IL303374A (en) 2023-08-01
WO2022118077A3 (en) 2022-09-29
JP2023553193A (ja) 2023-12-20

Similar Documents

Publication Publication Date Title
KR102657218B1 (ko) Igf-1r 억제용 p-에톡시 핵산
CN109072240A (zh) 使用piRNA诊断和治疗癌症的组合物和方法
WO2018067991A1 (en) Modulation of novel immune checkpoint targets
JP2014500024A (ja) 腫瘍細胞溶解を媒介する二重特異性アプタマー
TW201130495A (en) Organic compositions to treat HSF1-related diseases
KR20220008383A (ko) 베타-ENaC-관련 질환을 치료하기 위한 유기 조성물
TW201103983A (en) Aptamer against chymase and use thereof
JP2020114835A (ja) 療法用ナノ粒子および関連する組成物、方法、およびシステム
CN111447922A (zh) 用于igf-1r抑制的p-乙氧基核酸
JP2019534708A (ja) Pd−1特異的アプタマー
JP2023526328A (ja) siRNAを使用してPRDM2/RIZタンパク質の発現を調節するがん治療
CN121532196A (zh) 半乳糖凝集素-1作为免疫检查点在制备肿瘤免疫治疗药物中的应用以及该药物
JP7753256B2 (ja) 二重特異性個別化アプタマー
US20230193286A1 (en) Cytotoxic t-lymphocyte binding aptamers
JP2023553193A (ja) Tリンパ球結合アプタマー
CN111542607A (zh) 针对adamts5的适配体及其应用
JPWO2015163458A1 (ja) オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用
KR20260046091A (ko) 프로그램된 사멸 리간드 수용체(pd-l1) 발현을 위한 조성물 및 방법
CN113508175B (zh) 用于治疗癌症的组合物和方法
CN117280033A (zh) T-淋巴细胞结合适体
WO2024107993A1 (en) Stat3 targeting oligonucleotides and uses thereof
CN112912501B (zh) 寡核苷酸分子及其在肿瘤治疗中的应用
JP2023553193A5 (cg-RX-API-DMAC7.html)
EP3737393A1 (en) Mirna modulation of t cell signaling and uses thereof
JPWO2015147290A1 (ja) オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260317

R150 Certificate of patent or registration of utility model

Ref document number: 7837345

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150